重复给予钆贝葡胺后齿状核信号强度增高:一项回顾性分析
这项回顾性研究纳入43例从未接受过钆对比剂、后续接受3次以上钆贝葡胺增强脑MRI的患者,评估齿状核/大脑脚信号强度比变化。结果显示齿状核/大脑脚信号强度比随钆贝葡胺累积剂量线性增高,每1 mL平均增加0.015%。
要点
- 齿状核/大脑脚信号强度比在多次钆贝葡胺给药后平均增高6.7%(主组)和4.0%(次组)。
- 齿状核/大脑脚信号强度比与钆贝葡胺剂量呈线性关系,每1 mL平均增加0.015%。
- 报告脑MRI时需关注齿状核T1信号变化,尤其有多次钆贝葡胺暴露史者。
核心结论
- 多次接受钆贝葡胺给药的患者中,钆贝葡胺给药量与MRI上齿状核/大脑脚信号强度比的增高存在线性关系。
研究设计与样本
- 回顾性研究,纳入2006年1月至2016年5月期间因临床指征转诊行脑MRI的患者。
- 共43例患者(男14例,女29例;中位年龄49岁,年龄范围25-73岁),基线脑MRI时年龄18-90岁,既往从未接受过钆对比剂,接受过3次及以上钆贝葡胺增强MRI。
- 主组为幕上病灶数≤4个且病灶<3 cm、在1.5 T行轴位T1加权MRI的患者;次组为有脑放疗或开颅手术史、在1.5 T和3 T行同层面T1加权MRI的患者。
- 每例患者最多测量8次脑MRI的信号强度,计算从基线到各次随访扫描的相对信号强度变化;所有患者肝肾功能正常。
- 对P<.05的变量进行线性混合回归分析。
关键影像表现/征象
- 主组齿状核/大脑脚信号强度比平均增高6.7%±3.9,次组平均增高4.0%±2.7(均P<.001),对应钆贝葡胺总量134 mL±141、时间跨度55个月±35.2。
- 齿状核/大脑脚信号强度比随钆贝葡胺剂量线性增高,每1 mL钆贝葡胺平均增加0.015%±0.004(R²=0.3,P<.001)。
临床应用与阅片要点
- 在脑MRI报告中可关注齿状核T1信号强度变化,并结合患者钆贝葡胺累积剂量与暴露次数进行描述。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Increased cerebral signal intensity (SI) has been reported in patients undergoing MRI with gadolinium-based contrast agents (GBCAs). Published data on gadobenate dimeglumine have been somewhat contradictory. Purpose To evaluate the relationship between dosage of gadobenate dimeglumine and SI change at MRI following multiple gadobenate dimeglumine administrations. Materials and Methods In this retrospective study, patients referred for clinically indicated brain MRI from January 2006 through May 2016 were evaluated for inclusion. Eligible patients were between 18 and 90 years old at their baseline brain MRI and had never received a GBCA, had undergone three or more MRI examinations with gadobenate dimeglumine, and had the baseline scan and another brain MRI scan available for comparison. The primary group consisted of patients with four or fewer supratentorial lesions smaller than 3 cm who underwent axial T1-weighted MRI at 1.5 T. One patient had also undergone prior radiation therapy. The secondary group consisted of patients with a history of brain radiation therapy or craniotomy who underwent 1.5-T and 3-T same-plane T1-weighted MRI (in any order). The SI for up to eight brain MRI examinations per patient was measured, and relative SI changes from baseline to interval scans were calculated. A subgroup analysis was performed to assess the gadobenate dimeglumine washout since the last gadolinium exposure. All patients had normal renal and liver functions. Linear mixed regression analyses were performed for variables with P < .05. Results In 43 patients (14 men, 29 women; median age, 49 years; age range, 25-73 years), the dentate nucleus (DN)-to-middle cerebral peduncle (MCP) SI ratio showed a mean increase of 6.7% ± 3.9 in the primary group and 4.0% ± 2.7 in the secondary group (both P < .001) following the administration of 134 mL ± 141 gadobenate dimeglumine over 55 months ± 35.2. The DN/MCP SI ratio increased linearly with the amount of gadobenate dimeglumine, with a mean increase of 0.015% ± 0.004 per 1 mL of gadobenate dimeglumine (R2 = 0.3, P < .001). Conclusion In patients receiving multiple doses of gadobenate dimeglumine, a linear relationship existed between gadobenate dimeglumine administrations and an increase in the dentate nucleus-to-middle cerebral peduncle signal intensity ratio at MRI. © RSNA, 2020 See also the editorial by McDonald and Kallmes in this issue.
引用
- Nguyen NC, Molnar TT, Cummin LG, et al. Dentate Nucleus Signal Intensity Increases Following Repeated Gadobenate Dimeglumine Administrations: A Retrospective Analysis. Radiology. 2020. PMID: 32343210. doi:10.1148/radiol.2020190246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。